Patients with stage 1–3 non-small cell lung cancer (NSCLC) given a combination immunotherapy prior to surgery (neoadjuvant) had a better major pathological response (10% or less residual cancer) when the cancer was removed than those who took a single immunotherapy agent alone, according to results of a novel multicenter phase 2 NeoCOAST platform trial that included two investigators from the Johns Hopkins Kimmel Cancer Center and its Bloomberg-Kimmel Institute for Cancer Immunotherapy.
Dupixent receives FDA approval as first CRSwNP treatment
CRSwNP is a chronic inflammatory disease of the upper airway. Credit: Luisella Planeta LOVE PEACE 💛💙 from Pixabay. The US Food and Drug Administration (FDA)